AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36254201 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 371
Study 36254201 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 371
Study 36254733 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal pelvic denervation
Number of subjects: 18
Study 36254918 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CPB GLS
Number of subjects: 72
Study 36254918 — intervention group
Group type: COMPARATOR
Intervention: Pre-CPB GLS
Number of subjects: 72
Study 36254918 — intervention group
Group type: COMPARATOR
Intervention: Change in GLS
Number of subjects: 72
Study 36255027 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet suction technique (WEST)
Number of subjects: 300
Study 36255027 — intervention group
Group type: COMPARATOR
Intervention: Standard suction technique (SST)
Number of subjects: 300
Study 36255027 — intervention group
Group type: COMPARATOR
Intervention: Slow-pull technique (SPT)
Number of subjects: 300
Study 36255231 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 24
Study 36255258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin (doses of ≤300 mg/kg/day and ≤1,250 mg/kg/day)
Number of subjects: 0
Study 36255258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin (1,000 mg/kg/day)
Number of subjects: 0
Study 36255258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin (highest tolerated dose of 300/1,250 mg/kg/day)
Number of subjects: 0
Study 36255372 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (ELT) monotherapy
Number of subjects: 52
Study 36255372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) monotherapy
Number of subjects: 52
Study 36255372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Eltrombopag (ELT) and Lenalidomide (LEN)
Number of subjects: 52
Study 36255372 — intervention group
Group type: COMPARATOR
Intervention: Eltrombopag (ELT)
Number of subjects: 52
Study 36255372 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide (LEN)
Number of subjects: 52
Study 36255391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and Temozolomide
Number of subjects: 28
Study 36255444 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite traits mediation
Number of subjects: 0
Study 36255444 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36255448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ibrexafungerp
Number of subjects: 0
Study 36255448 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36255609 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD-CTB-Child
Number of subjects: 243
Study 36255609 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD-CTB-Observer
Number of subjects: 243
Study 36255609 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD-PTB
Number of subjects: 243
Study 36256599 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat 15 mg once-daily in combination with imiglucerase enzyme replacement therapy
Number of subjects: 11
Study 36256671 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.05 mg/kg orally once daily before or after collagenase-induced ICH
Number of subjects: 0
Study 36256693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter PVL closure procedures on mitral valves
Number of subjects: 216
Study 36256693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter PVL closure procedures on aortic valves
Number of subjects: 216
Study 36256693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter PVL closure in symptomatic patients
Number of subjects: 216
Study 36256698 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M-TAVR
Number of subjects: 351
Study 36256698 — intervention group
Group type: COMPARATOR
Intervention: S3i (conventional TAVR)
Number of subjects: 351
Study 36256728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic T1-times in patients (590±89 ms)
Number of subjects: 1075
Study 36256728 — intervention group
Group type: COMPARATOR
Intervention: Hepatic T1-times in controls (574±45 ms)
Number of subjects: 1075
Study 36256728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic T1-time >610 ms
Number of subjects: 1075
Study 36256783 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided triaging (CAT)
Number of subjects: 2901
Study 36256783 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD)
Number of subjects: 2901
Study 36256783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CAT and CAD
Number of subjects: 2901
Study 36256783 — intervention group
Group type: COMPARATOR
Intervention: Radiological reading alone
Number of subjects: 2901
Study 36256783 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided triaging (CAT) and CAD
Number of subjects: 2901
Study 36257062 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Ga-FAPI-46 PET/CT
Number of subjects: 6
Study 36257062 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 F-FDG PET/CT
Number of subjects: 6
Study 36257062 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 non-COVID-19 patients)
Number of subjects: 6
Study 36257718 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period (March 1, 2020, to February 28, 2021)
Number of subjects: 287348
Study 36257718 — intervention group
Group type: COMPARATOR
Intervention: Pre-pandemic period (March 1, 2019, to February 29, 2020)
Number of subjects: 287348
Study 36257718 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period
Number of subjects: 287348
Study 36257978 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational lead exposure assessment in the SPHERL study
Number of subjects: 0
Study 36258056 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with BPD
Number of subjects: 45
Study 36258056 — intervention group
Group type: COMPARATOR
Intervention: Children without BPD
Number of subjects: 45
Study 36258056 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 45
Study 36258166 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal body mass index
Number of subjects: 402
Study 36258166 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 402
Study 36258166 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 402
Study 36258240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 274
Study 36258239 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with HABSI
Number of subjects: 829
Study 36259253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib as consolidation therapy
Number of subjects: 0
Study 36259388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular Assist Device (VAD) or transplant
Number of subjects: 377
Study 36259388 — intervention group
Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 377
Study 36259388 — intervention group
Group type: COMPARATOR
Intervention: Black race
Number of subjects: 377
Study 36259411 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban areas (thrombectomy-capable centers)
Number of subjects: 920
Study 36259411 — intervention group
Group type: COMPARATOR
Intervention: Nonurban areas
Number of subjects: 920
Study 36259411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 920
Study 36259527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir Immediate (DTG-I)
Number of subjects: 412
Study 36259527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir Delayed (DTG-D)
Number of subjects: 412
Study 36259527 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitors (Control)
Number of subjects: 412
Study 36259971 — intervention group
Group type: EXPERIMENTAL
Intervention: B7-H3 CAR T cells, administered as 40 infusions, repeated locoregional dosing.
Number of subjects: 3
Study 36260160 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal social control
Number of subjects: 143
Study 36260160 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 143
Study 36260381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit&Sober app
Number of subjects: 22
Study 36260765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 692
Study 36260792 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream applied twice daily for 24 weeks
Number of subjects: 674
Study 36260792 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 24 weeks
Number of subjects: 674
Study 36260792 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream applied throughout 52 weeks
Number of subjects: 674
Study 36260792 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied throughout 52 weeks
Number of subjects: 674
Study 36260828 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide
Number of subjects: 144
Study 36260828 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and Temozolomide
Number of subjects: 144
Study 36260828 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT deficiency
Number of subjects: 144
Study 36261015 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell bispecific antibodies (TCBs) targeting gastric CEA
Number of subjects: 0
Study 36261215 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplivant-conjugated HPV16-SLP vaccine (1, 5, 20 or 50 µg per conjugated peptide)
Number of subjects: 25
Study 36261215 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplivant-conjugated HPV16-SLP vaccine (highest dose group)
Number of subjects: 25
Study 36261215 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplivant-conjugated HPV16-SLP vaccine (various doses)
Number of subjects: 25
Study 36261307 — intervention group
Group type: COMPARATOR
Intervention: Postoperative delirium
Number of subjects: 554
Study 36261307 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study population
Number of subjects: 554
Study 36261307 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with decreased functional connectivity strength
Number of subjects: 554
Study 36261307 — intervention group
Group type: COMPARATOR
Intervention: Patients with and without postoperative delirium
Number of subjects: 554
Study 36261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab 3 mg/kg every 2 weeks for up to 52 cycles
Number of subjects: 108
Study 36261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab
Number of subjects: 108
Study 36261602 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (revascularization and/or intestinal resection)
Number of subjects: 577
Study 36261602 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy or laparoscopy
Number of subjects: 577
Study 36261602 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care
Number of subjects: 577
Study 36261602 — intervention group
Group type: COMPARATOR
Intervention: Overall hospital management
Number of subjects: 577
Study 36261752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for high-risk stage II and stage III patients
Number of subjects: 3544
Study 36261752 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative-intent treatment
Number of subjects: 3544
Study 36261752 — intervention group
Group type: COMPARATOR
Intervention: Palliative treatment
Number of subjects: 3544
Study 36261752 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 3544
Study 36261825 — intervention group
Group type: EXPERIMENTAL
Intervention: Back Rx mobile application for discogenic chronic low back pain
Number of subjects: 75
Study 36261843 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/LGI diet
Number of subjects: 744
Study 36261882 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the revised Fibromyalgia Impact Questionnaire (CFIQR)
Number of subjects: 200
Study 36262060 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian patients with T2D
Number of subjects: 89
Study 36262558 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction (CMD) defined as coronary flow reserve (CFR) <2.3
Number of subjects: 0
Study 36262558 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition analysis and adenosine stress echocardiography
Number of subjects: 0
Study 36262558 — intervention group
Group type: EXPERIMENTAL
Intervention: LV end-diastolic pressure assessment using coronary angiography
Number of subjects: 0
Study 36262741 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-Induced Acute Kidney Injury (CI-AKI)
Number of subjects: 594
Study 36262741 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-AKI
Number of subjects: 594
Study 36262741 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving optimum body weight before CAG
Number of subjects: 594
Study 36262832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry electrode EEG for prehospital detection of LVO-a stroke
Number of subjects: 386
Study 36262914 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-motor intervention with rhythmic entrainment cues and augmented auditory feedback during nine sessions.
Number of subjects: 28
Study 36263107 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term follow-up of surrogate biomarkers (plasma N-terminal pro-brain natriuretic peptide, growth differentiation factor 15, troponin-T, high-sensitivity C-reactive protein, urinary albumin/creatinine ratio) obtained within 1 month and 6 months after discharge.
Number of subjects: 0
Study 36263287 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration ≥ 150 ms
Number of subjects: 211
Study 36263287 — intervention group
Group type: EXPERIMENTAL
Intervention: 130 ms ≤ QRS < 150 ms
Number of subjects: 211
Study 36263287 — intervention group
Group type: COMPARATOR
Intervention: QRS duration < 130 ms
Number of subjects: 211
Study 36263311 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Number of subjects: 98
Study 36263311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge-enhanced ACL restoration (BEAR)
Number of subjects: 98
Study 36263311 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated ACLs
Number of subjects: 98
Study 36263311 — intervention group
Group type: COMPARATOR
Intervention: Statistical parametric mapping
Number of subjects: 98
Study 36263311 — intervention group
Group type: COMPARATOR
Intervention: Correlations with body and knee size
Number of subjects: 98
Study 36263396 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing in self-collected urine samples
Number of subjects: 195
Study 36263398 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced supportive care for EVD patients
Number of subjects: 0
Study 36263398 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDS score
Number of subjects: 0
Study 36263685 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS patients
Number of subjects: 27
Study 36263685 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cortisol1 mg DST
Number of subjects: 27
Study 36263798 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36263839 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography (PET/CT)
Number of subjects: 0
Study 36263839 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without PET/CT
Number of subjects: 0
Study 36263840 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 (2×10^6 CAR T cells/kg)
Number of subjects: 31
Study 36263840 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 (1×10^6 CAR T cells/kg in 68 mL formulation)
Number of subjects: 31
Study 36263840 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 (1×10^6 CAR T cells/kg in 40 mL formulation)
Number of subjects: 31
Study 36263840 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 (all treated patients)
Number of subjects: 31
Study 36263840 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 (responders)
Number of subjects: 31
Study 36263851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (n=88) - low symptoms; Cluster 2 (n=91) - mild symptoms; Cluster 3 (n=80) - isolated aesthetic discomfort; Cluster 4 (n=42) - high pain, stiffness, and functional limitation; Cluster 5 (n=88) - high pain, stiffness, functional limitation, and high aesthetic discomfort.
Number of subjects: 389
Study 36263879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid Upper Arm Circumference (MUAC)
Number of subjects: 1117
Study 36263879 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 1117
Study 36263947 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the De-Morton Mobility Index (DEMMI)
Number of subjects: 102
Study 36264113 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenagers with obesity
Number of subjects: 5275
Study 36264113 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of teenagers with obesity
Number of subjects: 5275
Study 36264113 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors providing medical care for teenagers with obesity
Number of subjects: 5275
Study 36264113 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication between teenagers, caregivers, and doctors
Number of subjects: 5275
Study 36264123 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg/300 mg once daily + osimertinib 80 mg once daily
Number of subjects: 180
Study 36264123 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib + osimertinib combination
Number of subjects: 180
Study 36264125 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan (10 mg once daily)
Number of subjects: 1268
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin deficiency (EGRac ≥1.40) in individuals with MTHFR 677TT genotype
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal riboflavin status (EGRac ≤1.26)
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal riboflavin status (EGRac: 1.27-1.39)
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin status (EGRac)
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 intake
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement use
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified food
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: EGRac
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 5612
Study 36264281 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (≥65 years)
Number of subjects: 5612
Study 36264365 — intervention group
Group type: EXPERIMENTAL
Intervention: High arterial oxygen levels and high oxygen supplementation
Number of subjects: 1084
Study 36264378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 67
Study 36264378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 67
Study 36264378 — intervention group
Group type: COMPARATOR
Intervention: EXTREME
Number of subjects: 67
Study 36264382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib (TAK-228) 3 mg by mouth once daily on a continuous dosing schedule in 28-day cycle
Number of subjects: 13
Study 36264382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib (TAK-228)
Number of subjects: 13
Study 36264409 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous fusion device
Number of subjects: 0
Study 36264536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib with esomeprazole
Number of subjects: 0
Study 36264536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib with itraconazole
Number of subjects: 0
Study 36264536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib with rifampin
Number of subjects: 0
Study 36264536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib with probenecid
Number of subjects: 0
Study 36264536 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate CYP3A4 inhibitor (fluconazole)
Number of subjects: 0
Study 36264536 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate CYP3A inducer (efavirenz)
Number of subjects: 0
Study 36264570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 0
Study 36264570 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36264626 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of Intensive Support in Emergency Departments (POISED) intervention for 6 months of care management by registered nurses and specialty-trained paraprofessionals.
Number of subjects: 2
Study 36264626 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of Intensive Support in Emergency Departments (POISED) intervention for 6 months of care management.
Number of subjects: 2
Study 36264626 — intervention group
Group type: COMPARATOR
Intervention: Usual care as recommended at emergency department discharge.
Number of subjects: 2
Study 36264905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech BNT162b2 vaccine
Number of subjects: 0
Study 36264905 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR positive cases
Number of subjects: 0
Study 36264905 — intervention group
Group type: COMPARATOR
Intervention: RT-PCR negative controls
Number of subjects: 0
Study 36264995 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of pharmacists in the care trajectory of older adults with MNCDs in family medicine groups (FMGs)
Number of subjects: 0
Study 36264995 — intervention group
Group type: COMPARATOR
Intervention: Usual care without pharmacist involvement in control FMGs
Number of subjects: 0
Study 36265042 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal biomarker assessment using machine learning models (Android and iOS)
Number of subjects: 259
Study 36265042 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with anosmia and ageusia
Number of subjects: 259
Study 36265042 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models for symptom monitoring
Number of subjects: 259